Who is the manufacturer of Enasidenib?

Enasidenib (Enasidenib) is a targeted drug targeting isocitrate dehydrogenase 2 (IDH2) mutations. It is mainly used to treat patients with relapsed or refractory acute myeloid leukemia (AML). The drug was originally developed by Agios Pharmaceuticals and was approved by the U.S. Food and Drug Administration (FDA) in 2017.

Agios Pharmaceuticals is a biopharmaceutical company focusing on the fields of metabolism and oncology. It has profound technological accumulation in the research and development of small molecule drugs. The company is committed to using innovative science to develop novel treatments for cancer and other serious diseases. During the development of ensidipine, Agios Pharmaceuticals demonstrated its expertise in targeted therapies.

During the development process,Agios Pharmaceuticals entered into a licensing collaboration agreement with Celgene (later Bristol-Myers Squibb). As a leading global biopharmaceutical company, Celgene has extensive experience in marketing and product promotion, which provides strong support for the launch and promotion of ensidipine. Under this cooperation model, Agios is responsible for drug research and development, while Celgene is responsible for subsequent commercial promotion and marketing operations, allowing ensidipine to enter clinical application more quickly.

The approval of ensidipine marks an important advance in the field of targeted therapy in acute myeloid leukemia, especially for patients with IDH2 mutations. The drug achieves therapeutic effects by targeting metabolic pathways within tumor cells and interfering with cell growth and proliferation. This mechanism makes ensidipine highly specific in treatment, which can effectively reduce the impact on normal cells and alleviate the side effects of patients.

Reference materials:https://pubchem.ncbi.nlm.nih.gov/compound/Enasidenib